Intellia Therapeutics, Inc. (NTLA) Institutional Ownership

Ownership Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has 286 institutional investors with active 13F positions as of December 2025.

• These investors held 94.6% of outstanding shares in December 2025, down from 96.3% in September 2025.
• Their total shares held in NTLA increased 4.97% from the prior quarter, while the number of investors in Intellia Therapeutics decreased 0.69% year over year.
• Of these 286 holders, 159 added to their stakes in Intellia Therapeutics, 87 trimmed positions, and 40 made no changes.
• Altogether, these fund groups held 104.18Mn shares in NTLA by December 2025, up by 4.94Mn shares quarter on quarter, and down 446.24K shares year over year.
• As of December 31, 2025, ARK Investment Management LLC held the largest stake in Intellia Therapeutics with 14.51Mn shares, accounting for 13.17% of total shares outstanding.
• The most significant purchases of NTLA for the quarter ending December 2025 came from VANGUARD PORTFOLIO MANAGEMENT LLC (6.22Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.08Mn), TWO SIGMA INVESTMENTS, LP (2.01Mn), BlackRock, Inc. (1.88Mn), UBS Group AG (1.83Mn).
• The largest sales of NTLA for the quarter ending December 2025 came from Goldman Sachs Group Inc (1.28Mn), ARMISTICE CAPITAL, LLC (820.0K), CITADEL ADVISORS LLC (492.01K), Barclays Plc (364.0K), HRT FINANCIAL LP (262.55K).
• Per Business Quant, the top 10 investors in NTLA for the quarter ending December 2025 include ARK Investment Management LLC (14.51Mn), BlackRock, Inc. (12.16Mn), State Street Corp (6.92Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (6.22Mn), D. E. Shaw & Co., Inc. (5.73Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.08Mn), TWO SIGMA INVESTMENTS, LP (4.71Mn), Regeneron Pharmaceuticals, Inc. (3.7Mn), GEODE CAPITAL MANAGEMENT, LLC (2.85Mn), UBS Group AG (2.69Mn).